

Ulcerative Colitis

A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Participants Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors

A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors

Trial Status
Completed

Trial Runs In
22 Countries

Trial Identifier
NCT02100696 2013-004278-88
GA28950

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This Phase III, double-blind, placebo-controlled, multicenter study will investigate the efficacy and safety of etrolizumab during induction and maintenance of remission compared with placebo in the treatment of participants with moderately to severely active ulcerative colitis (UC) who have been previously exposed to TNF inhibitors.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT02100696 2013-004278-88 GA28950
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>= 18 Years & <= 80 Years

Healthy Volunteers
No
